NEJM Evidence’s Post

View organization page for NEJM Evidence, graphic

3,612 followers

Since January 2020, there have been over 775 million confirmed cases of Covid-19 and 7 million deaths globally. Vaccinations and increased virologic exposure in the population have attenuated the nature of the clinical illness and reduced the severe outcomes associated with the early pandemic stages. However, there is ongoing global transmission of SARS-CoV-2 and evolution of variant strains, with the potential to cause more serious illness. Only limited antiviral options are available to reduce symptomatic illness and disease progression.    In an editorial, Drs. Amy C. Sherman and Lindsey R. Baden examine a trial of olgotrelvir for outpatient Covid-19 and discuss the potential benefits of the treatment.    Read the full editorial: https://eviden.cc/3UW7FlF    𝗙𝗨𝗥𝗧𝗛𝗘𝗥 𝗥𝗘𝗔𝗗𝗜𝗡𝗚  Original Article by Rongmeng Jiang, MD, Hongzhou Lu, MD, Xiao Xu, MD, et al.: Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19  https://eviden.cc/3UVXptz    #ClinicalTrials #MedicalResearch 

  • “… the real value for olgotrelvir may lie in specific populations that were not studied in this trial: patients with comorbidities taking medications that have serious drug–drug interactions with ritonavir….”

EDITORIAL
Amy C. Sherman, MD, and Lindsey R. Baden, MD

To view or add a comment, sign in

Explore topics